Skip to main content
SpringerLink
Log in

Endokrine Therapie der vulvovaginalen Atrophie

Endocrine treatment of vulvovaginal atrophy

  • Arzneimitteltherapie
  • Published:
Gynäkologische Endokrinologie Aims and scope

Zusammenfassung

Die vulvovaginale Atrophie (VVA) ist ein im klinischen Alltag häufig unterschätzter Aspekt der weiblichen Gesundheit. Zahlreiche Arbeiten haben sich in den letzten Jahren mit der Pathophysiologie der symptomatischen VAA bei peri- und postmenopausalen Frauen auseinandergesetzt. Neben den physischen Aspekten werden die Auswirkungen der VVA auf die Lebensqualität und das psychosoziale Wohlbefinden diskutiert. Der vorliegende Beitrag soll einen Überblick über den aktuellen Stand der Wissenschaft zur endokrinen Therapie der VVA liefern.

Abstract

Vulvovaginal atrophy (VVA) is a frequently underestimated aspect of female health in the clinical routine. Numerous studies in recent years have dealt with the pathophysiology of symptomatic VAA in perimenopausal and postmenopausal women. In addition to the physical aspects, the impact of VAA on the quality of life and psychosocial well-being are discussed. This article provides an overview of the current state of the art of endocrine treatment of VVA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Agrawal P, Singh SM, Able C et al (2023) Safety of Vaginal Estrogen Therapy for Genitourinary Syndrome of Menopause in Women With a History of Breast Cancer. Obstet Gynecol 142:660–668. https://doi.org/10.1097/AOG.0000000000005294

    Article  PubMed  Google Scholar 

  2. Anglim B, Phillips C, Shynlova O et al (2021) The effect of local estrogen therapy on the urinary microbiome composition of postmenopausal women with and without recurrent urinary tract infections. Int Urogynecol J. https://doi.org/10.1007/s00192-021-04832-9

    Article  PubMed  Google Scholar 

  3. Baber RJ, Panay N, Fenton A (2016) 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric 19:109–150. https://doi.org/10.3109/13697137.2015.1129166

    Article  CAS  PubMed  Google Scholar 

  4. Bachmann GA, Nevadunsky NS (2000) Diagnosis and treatment of atrophic vaginitis. Am Fam Physician 61:3090–3096

    CAS  PubMed  Google Scholar 

  5. Bhupathiraju SN, Grodstein F, Stampfer MJ et al (2018) Vaginal estrogen use and chronic disease risk in the Nurses’ Health Study. Menopause 26:603–610. https://doi.org/10.1097/GME.0000000000001284

    Article  PubMed  PubMed Central  Google Scholar 

  6. Biehl C, Plotsker O, Mirkin S (2019) A systematic review of the efficacy and safety of vaginal estrogen products for the treatment of genitourinary syndrome of menopause. Menopause 26:431–453. https://doi.org/10.1097/GME.0000000000001221

    Article  PubMed  Google Scholar 

  7. Bruyniks N, Biglia N, Palacios S et al (2017) Systematic indirect comparison of ospemifene versus local estrogens for vulvar and vaginal atrophy. Climacteric 20:195–204. https://doi.org/10.1080/13697137.2017.1284780

    Article  CAS  PubMed  Google Scholar 

  8. Chen Y‑Y, Su T‑H, Lau H‑H (2021) Estrogen for the prevention of recurrent urinary tract infections in postmenopausal women: a meta-analysis of randomized controlled trials. Int Urogynecol J 32:17–25. https://doi.org/10.1007/s00192-020-04397-z

    Article  PubMed  Google Scholar 

  9. Cody JD, Jacobs ML, Richardson K et al (2012) Oestrogen therapy for urinary incontinence in post-menopausal women. Cochrane Database Syst Rev 10:CD1405. https://doi.org/10.1002/14651858.CD001405.pub3

    Article  PubMed  Google Scholar 

  10. Cold S, Cold F, Jensen M‑B et al (2022) Systemic or Vaginal Hormone Therapy After Early Breast Cancer: A Danish Observational Cohort Study. J Natl Cancer Inst 114:1347–1354. https://doi.org/10.1093/jnci/djac112

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Donders G, Neven P, Moegele M et al (2014) Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor(®)) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study. Breast Cancer Res Treat 145:371–379. https://doi.org/10.1007/s10549-014-2930-x

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Furuhjelm M, Karlgren E, Carlström K (1980) Intravaginal administration of conjugated estrogens in premenopausal and postmenopausal women. Int J Gynaecol Obstet 17:335–339. https://doi.org/10.1002/j.1879-3479.1980.tb00295.x

    Article  CAS  PubMed  Google Scholar 

  13. Gajer P, Brotman RM, Bai G et al (2012) Temporal dynamics of the human vaginal microbiota. Sci Transl Med 4:132ra52. https://doi.org/10.1126/scitranslmed.3003605

    Article  PubMed  PubMed Central  Google Scholar 

  14. Guidozzi F (2013) Estrogen therapy in gynecological cancer survivors. Climacteric 16:611–617. https://doi.org/10.3109/13697137.2013.806471

    Article  CAS  PubMed  Google Scholar 

  15. Heimer GM, Englund DE (1986) Plasma oestriol following vaginal administration: morning versus evening insertion and influence of food. Maturitas 8:239–243. https://doi.org/10.1016/0378-5122(86)90031-9

    Article  CAS  PubMed  Google Scholar 

  16. Hendrix SL, Cochrane BB, Nygaard IE et al (2005) Effects of estrogen with and without progestin on urinary incontinence. JAMA 293:935–948. https://doi.org/10.1001/jama.293.8.935

    Article  CAS  PubMed  Google Scholar 

  17. Heo Y‑A (2019) Prasterone: A Review in Vulvovaginal Atrophy. Drugs Aging 36:781–788. https://doi.org/10.1007/s40266-019-00693-6

    Article  CAS  PubMed  Google Scholar 

  18. Jackson S (2002) The effect of oestradiol on vaginal collagen metabolism in postmenopausal women with genuine stress incontinence. BJOG 109:339–344. https://doi.org/10.1016/S1470-0328(02)01052-2

    Article  CAS  PubMed  Google Scholar 

  19. Kanne B, Jenny J (1991) Lokale Anwendung von schwachdosiertem Östriol und lebensfähigen Döderlein-Keimen in der Postmenopause. Gynakol Geburtshilfliche Rundsch 31:7–13. https://doi.org/10.1159/000271609

    Article  CAS  Google Scholar 

  20. Kovachev SM, Kovachev MS (2022) Genitourinary syndrome, local oestrogen therapy and endometrial pathology: a single-centre, randomised study. J Obstet Gynaecol 42:1489–1492. https://doi.org/10.1080/01443615.2021.2006163

    Article  CAS  PubMed  Google Scholar 

  21. Krychman M, Graham S, Bernick B et al (2017) The Women’s EMPOWER Survey: Women’s Knowledge and Awareness of Treatment Options for Vulvar and Vaginal Atrophy Remains Inadequate. J Sex Med 14:425–433. https://doi.org/10.1016/j.jsxm.2017.01.011

    Article  PubMed  Google Scholar 

  22. Lamont RF, Sobel JD, Akins RA et al (2011) The vaginal microbiome: new information about genital tract flora using molecular based techniques. BJOG 118:533–549. https://doi.org/10.1111/j.1471-0528.2010.02840.x

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Lee Y‑K, Chung HH, Kim JW et al (2011) Vaginal pH-balanced gel for the control of atrophic vaginitis among breast cancer survivors: a randomized controlled trial. Obstet Gynecol 117:922–927. https://doi.org/10.1097/AOG.0b013e3182118790

    Article  PubMed  Google Scholar 

  24. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe (2018) AWMF: Diagnostik, Therapie und Nachsorge der Patientinnen mit Endometriumkarzinom, Langversion 1.0, AWMF Registernummer: 032/034-OL. http://www.leitlinienprogramm-onkologie.de/leitlinien/endometriumkarzinom. Zugegriffen: 29. Nov. 2021

  25. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe (2022) AWMF: Endometriumkarzinom, Langversion 2.0, AWMF Registernummer: 032/034-OL

    Google Scholar 

  26. Bride MMB, Rhodes DJ, Shuster LT (2010) Vulvovaginal atrophy. Mayo Clin Proc 85:87–94. https://doi.org/10.4065/mcp.2009.0413

    Article  Google Scholar 

  27. Mattsson LA, Cullberg G (1983) Vaginal absorption of two estriol preparations. A comparative study in postmenopausal women. Acta Obstet Gynecol Scand 62:393–396. https://doi.org/10.3109/00016348309154208

    Article  CAS  PubMed  Google Scholar 

  28. Maurer-Major E (2001) Einfluss von Hormonen auf den Beckenboden. coloproctology 23:272–275. https://doi.org/10.1007/s00053-001-5056-7

    Article  Google Scholar 

  29. McGroarty JA (1993) Probiotic use of lactobacilli in the human female urogenital tract. FEMS Immunol Med Microbiol 6:251–264. https://doi.org/10.1111/j.1574-695X.1993.tb00337.x

    Article  CAS  PubMed  Google Scholar 

  30. Moegele M, Buchholz S, Seitz S et al (2012) Vaginal estrogen therapy in postmenopausal breast cancer patients treated with aromatase inhibitors. Arch Gynecol Obstet 285:1397–1402. https://doi.org/10.1007/s00404-011-2181-6

    Article  CAS  PubMed  Google Scholar 

  31. Montoya TI, Maldonado PA, Acevedo JF et al (2015) Effect of vaginal or systemic estrogen on dynamics of collagen assembly in the rat vaginal wall. Biol Reprod 92:43. https://doi.org/10.1095/biolreprod.114.118638

    Article  CAS  PubMed  Google Scholar 

  32. Mørch LS, Løkkegaard E, Andreasen AH et al (2009) Hormone therapy and ovarian cancer. JAMA 302:298–305. https://doi.org/10.1001/jama.2009.1052

    Article  PubMed  Google Scholar 

  33. Mueck AO, Ruan X, Prasauskas V et al (2018) Treatment of vaginal atrophy with estriol and lactobacilli combination: a clinical review. Climacteric 21:140–147. https://doi.org/10.1080/13697137.2017.1421923

    Article  CAS  PubMed  Google Scholar 

  34. Nappi RE, Palacios S (2014) Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause. Climacteric 17:3–9. https://doi.org/10.3109/13697137.2013.871696

    Article  CAS  PubMed  Google Scholar 

  35. Panay N (2015) Genitourinary syndrome of the menopause—dawn of a new era? Climacteric 18(Suppl 1):13–17. https://doi.org/10.3109/13697137.2015.1070564

    Article  PubMed  Google Scholar 

  36. (2018) Peri- and Postmenopause—Diagnosis and Interventions. Guideline of the German Society of Gynecology and Obstetrics (S‑3 Level, AWMF Registry No. 015-062). http://www.awmf.org/leitlinien/detail/ll/015-062.html. Zugegriffen: 27. Nov. 2021

  37. Portman DJ, Gass MLS (2014) Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and The North American Menopause Society. Climacteric 17:557–563. https://doi.org/10.3109/13697137.2014.946279

    Article  CAS  PubMed  Google Scholar 

  38. redondo-Lopez V, Cook RL, Sobel JD (1990) Emerging role of lactobacilli in the control and maintenance of the vaginal bacterial microflora. Rev Infect Dis 12:856–872. https://doi.org/10.1093/clinids/12.5.856

    Article  CAS  PubMed  Google Scholar 

  39. Rigg LA, Hermann H, Yen SS (1978) Absorption of estrogens from vaginal creams. N Engl J Med 298:195–197. https://doi.org/10.1056/NEJM197801262980406

    Article  CAS  PubMed  Google Scholar 

  40. Samsioe G (1998) Urogenital aging—a hidden problem. Am J Obstet Gynecol 178:S245–S249. https://doi.org/10.1016/S0002-9378(98)70555-1

    Article  CAS  PubMed  Google Scholar 

  41. Santoro N, Komi J (2009) Prevalence and impact of vaginal symptoms among postmenopausal women. J Sex Med 6:2133–2142. https://doi.org/10.1111/j.1743-6109.2009.01335.x

    Article  PubMed  Google Scholar 

  42. Shim S‑H, Lee SJ, Kim S‑N (2014) Effects of hormone replacement therapy on the rate of recurrence in endometrial cancer survivors: a meta-analysis. Eur J Cancer 50:1628–1637. https://doi.org/10.1016/j.ejca.2014.03.006

    Article  CAS  PubMed  Google Scholar 

  43. Simon J, Nachtigall L, Ulrich LG et al (2010) Endometrial safety of ultra-low-dose estradiol vaginal tablets. Obstet Gynecol 116:876–883. https://doi.org/10.1097/AOG.0b013e3181f386bb

    Article  PubMed  Google Scholar 

  44. Singh P, Oehler MK (2010) Hormone replacement after gynaecological cancer. Maturitas 65:190–197. https://doi.org/10.1016/j.maturitas.2009.11.017

    Article  CAS  PubMed  Google Scholar 

  45. Sturdee DW, Panay N (2010) Recommendations for the management of postmenopausal vaginal atrophy. Climacteric 13:509–522. https://doi.org/10.3109/13697137.2010.522875

    Article  CAS  PubMed  Google Scholar 

  46. Unlü C, Donders G (2011) Use of lactobacilli and estriol combination in the treatment of disturbed vaginal ecosystem: a review. J Turkish German Gynecol Assoc 12:239–246. https://doi.org/10.5152/jtgga.2011.57

    Article  Google Scholar 

  47. van der Vies J (1982) The pharmacology of oestriol. Maturitas 4:291–299. https://doi.org/10.1016/0378-5122(82)90061-5

    Article  PubMed  Google Scholar 

  48. Vaughan MH, Mao J, Karstens LA et al (2021) The Urinary Microbiome in Postmenopausal Women with Recurrent Urinary Tract Infections. J Urol 206:1222–1231. https://doi.org/10.1097/JU.0000000000001940

    Article  PubMed  PubMed Central  Google Scholar 

  49. Wierman ME (2007) Sex steroid effects at target tissues: mechanisms of action. Am J Physiol 31:26–33. https://doi.org/10.1152/advan.00086.2006

    Article  Google Scholar 

  50. Wilson JD, Lee RA, Balen AH et al (2007) Bacterial vaginal flora in relation to changing oestrogen levels. Int J STD AIDS 18:308–311. https://doi.org/10.1258/095646207780749583

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Frauenheilkunde und Geburtshilfe der Universität Regensburg am Caritas-Krankenhaus St. Josef, Landshuter Straße 65, 93053, Regensburg, Deutschland

    Lucia Bausewein,  Susanne Schüler-Toprak &  Olaf Ortmann

Authors
  1. Lucia Bausewein
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Susanne Schüler-Toprak
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Olaf Ortmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Susanne Schüler-Toprak.

Ethics declarations

Interessenkonflikt

L. Bausewein, S. Schüler-Toprak und O. Ortmann geben an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von den Autor/-innen keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Additional information

Redaktion

Brigitte Leeners, Zürich

Olaf Ortmann, Regensburg

Clemens Tempfer, Herne

Hinweis des Verlags

Der Verlag bleibt in Hinblick auf geografische Zuordnungen und Gebietsbezeichnungen in veröffentlichten Karten und Institutsadressen neutral.

figure qr

QR-Code scannen & Beitrag online lesen

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bausewein, L., Schüler-Toprak, S. & Ortmann, O. Endokrine Therapie der vulvovaginalen Atrophie. Gynäkologische Endokrinologie 22, 135–142 (2024). https://doi.org/10.1007/s10304-024-00566-1

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10304-024-00566-1

Schlüsselwörter

Keywords

Search

Navigation